top of page

INVESTMENT

Quality Innovation, Patient-Centered Design

WELCOME

Pioneering devices. Designed not just for patients, but for people.

David Howarth CEO

David Howarth Founder, CEO

With more than two decades dedicated to medical device development, my career has been guided by a steadfast belief that new technologies must not only meet the highest quality standards but also prioritize the patient at the centre of every innovation. In today's fast-paced industry climate, it's all too easy to become absorbed in the immediate challenges of delivering products to market and maintaining them in the field. However, I firmly believe that it is increasingly crucial to remember the fundamental reasons behind our work.

​

The healthcare industry is at a crossroads, with approximately 80% of current expenses overwhelmingly directed towards monitoring and managing disease states—a trend that is unsustainable and threatens to destabilize global healthcare systems. In stark contrast, only about 5% of healthcare spending is allocated towards crucial detection and prevention strategies.

​

Recognizing this imbalance, I founded DRUiD in 2018 to shift the paradigm back towards the patient. Over the past five years, I strategically incubated, tested, and de-risked the business to maximize both the impact of our products on the people we serve and the return on your investment.

 

DRUiD is committed to developing diagnostic devices that seamlessly integrate into daily life while proactively focusing on disease prevention. Our mission is to transform economic and health outcomes by aligning medical technology with genuine human needs, ensuring that healthcare becomes not only more effective but also more empathetic and preventive.

​

By investing in DRUiD, you are supporting a future where medical technology serves to enhance life, not just extend it.

CycleSmart Diagnostics- Gen 1.png

DRUiD In Numbers

$50BN

TAM

$500M

SOM

4

PATENTS PENDING

$5BN

SAM

5

LTV:CAC

1

PATENTS GRANTED

INDUSTRY

Our Partners

At DRUID, we leverage our deep market understanding to streamline our path to success. We strategically outsource key functions such as Quality Assurance, Regulatory Compliance, and Device Testing to expert partners, a move that significantly reduces our operational expenditures by 30% and capital expenditures by 55%.

 

This strategic allocation of resources boosts the efficiency of our financial investments, allowing us to focus intensively on manufacturing and sales. By collaborating with specialists in these essential areas, we sharpen our operational focus and enhance our market agility.

 

This approach not only strengthens our capacity to deliver high-quality medical devices rapidly and efficiently but also maximizes your return on investment. Our commitment to this strategy demonstrates our dedication to quality, financial acumen, and investor value, ensuring we remain at the forefront of medical device innovation.

iDE8 Logo Shoulder.png
uhi.jpg

University of Highlands & Islands

Genitsys QMS

GeniTSYS 

Our Journey So Far

2018 

DRUiD IS FOUNDED

Born from innovation! Founded on the triumph of our sister company iDE8s award in the JLABS Next-Gen Baby Box award in December 2017. DRUiD embodies the spirit of innovation and excellence. Our inception is a testament to groundbreaking ideas and the relentless pursuit of transforming healthcare.

2019

GROUNDBREAKING SENSOR TECHNOLOGY CREATED

Co-created with iDE8, Our Hydrogel Biosensor platform sets a new standard in precision and innovation. Designed with meticulous attention to detail, our sensor technology revolutionizes the way we interact with our environment, offering unmatched accuracy, responsiveness, and reliability.

Series A

OUR ASK

We are seeking £7 million to reach key milestones leading to our regulatory submission.

 

This includes £3.5 million for operational expenses to enhance our team and R&D efforts, £2.5 million for capital expenditures to advance product development, and £1 million for comprehensive clinical trials to ensure the highest standards of safety and efficacy. This funding will position us ideally for market entry and scalable growth. 

​

We invite interested investors to reach out for more detailed information on how your investment can drive innovation in medical diagnostics and create impactful health solutions. Join us in shaping the future of healthcare.

Series A Round In Numbers

£2.5M

CapEx

£3.5M

OpEx

£1M

Clinical trials

bottom of page